Tyra Biosciences, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Tyra Biosciences, Inc. (TYRA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $46.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-02
- Tyra Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $46.00K, a 557.14% increase from fiscal 2024.
- Tyra Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $7.00K.
- Tyra Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was -$374.00K.
- Tyra Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2022 was -$120.00K, a 239.53% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $46.00K 10-K · filed 2026-03-02 | |
| 2024-12-31 | $7.00K 10-K · filed 2026-03-02 | -$750.00K 10-K · filed 2025-03-27 |
| 2023-12-31 | -$374.00K 10-K · filed 2025-03-27 | $1.00K 10-K · filed 2024-03-19 |
| 2022-12-31 | -$120.00K 10-K · filed 2024-03-19 | $707.00K 10-K · filed 2023-03-22 |
| 2021-12-31 | $86.00K 10-K · filed 2023-03-22 | $114.00K 10-K · filed 2022-03-03 |
| 2020-12-31 | $102.00K 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |